A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5

Trial Profile

A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide; Formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms SPRUCE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Mar 2016 Post hoc analysis results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 04 Mar 2014 Results of a pooled analysis of this trial and another trial (see profile 700035455) presented at the 70th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 26 Feb 2013 Results comparing patients with versus without fixed airflow obstruction presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top